Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CA-125: a marker for persistent gestational trophoblastic disease?

P P Koonings1, J B Schalerth

  • 1Division of Gynecologic Oncology, University of Southern California Medical Center, Los Angeles 90007.

Gynecologic Oncology
|May 1, 1993
PubMed
Summary

Elevated cancer antigen 125 (CA-125) levels may predict persistent gestational trophoblastic disease. This finding offers clinical utility for monitoring patients post-molar evacuation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of atypical glandular cells of undetermined significance: is age important?

American journal of obstetrics and gynecology·2001
Same author

Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism.

Obstetrics and gynecology·1994
Same author

The process of carcinogenesis for endometrial adenocarcinoma could be short: development of a malignancy after endometrial ablation.

American journal of obstetrics and gynecology·1994
Same author

Long-term experience with a totally implanted catheter system in gynecologic oncologic patients.

Journal of the American College of Surgeons·1994
Same author

A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy.

American journal of obstetrics and gynecology·1994
Same author

Neovaginal procidentia.

Annals of plastic surgery·1993

Area of Science:

  • Gynecology
  • Oncology
  • Reproductive Medicine

Background:

  • Gestational trophoblastic disease (GTD) requires accurate monitoring for persistent disease.
  • Complete hydatidiform mole is a common form of GTD.
  • Clinical utility of tumor markers in GTD management is an ongoing area of research.

Purpose of the Study:

  • To evaluate the clinical utility of cancer antigen 125 (CA-125) levels in predicting persistent gestational trophoblastic disease.
  • To assess the correlation between pre-evacuation CA-125 levels and the development of persistent GTD following complete hydatidiform mole.

Main Methods:

  • A cohort of 51 patients with pathologically confirmed complete hydatidiform mole was studied.
  • CA-125 levels were measured prior to suction molar evacuation.

Related Experiment Videos

  • Statistical analysis included chi-squared and Mann-Whitney U tests to compare CA-125 levels between groups.

    • Main Results:

    • CA-125 levels were significantly higher in patients who developed persistent GTD compared to those without (85.9 U/ml vs. 48.3 U/ml, P = 0.004).
    • CA-125 levels showed no correlation with patient age, gravidity, gestational age, or the presence of thecal-luteal cysts.
    • A twofold increase in CA-125 levels was observed in the persistent disease group.

    Conclusions:

    • Pre-evacuation CA-125 levels appear to be a valuable predictor for identifying patients at risk of developing persistent gestational trophoblastic disease.
    • This biomarker may aid in early detection and management strategies for GTD.
    • Further research can explore the integration of CA-125 into routine GTD surveillance protocols.